Home LiteratureArticle Details
PMID: 19199969 Published · ppublish English Journal Article Review

Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics.

Current pharmaceutical design ·Vol. 15 ·No. 4 ·2009-00-00 ·Pages 424-9

Louis CU, Brenner MK

Abstract

Immunotherapy is an attractive option for patients with high risk neuroblastoma due to their poor long-term survival rates after conventional treatment. Neuroblastoma cells are derived from the embryonic neural crest and therefore express tumor antigens not widely seen in normal cells, making them potential targets for immunologic attack. There is already considerable experience with monoclonal antibodies that target these tumor associated antigens, and in this review we focus on more exploratory approaches, using tumor vaccines and adoptive transfer of tumor-directed T cells.

MeSH Terms
Adoptive Transfer Antibodies, Monoclonal/therapeutic use Cancer Vaccines/therapeutic use Humans Immunotherapy Neuroblastoma/therapy T-Lymphocytes/transplantation
Chemicals
Antibodies, Monoclonal Cancer Vaccines
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Louis C U
Center for Cell and Gene Therapy: Texas Children's Hospital, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030, USA. culouis@txccc.org
Brenner M K
References (54)
54 references, click to expand
  1. Combined chemokine and cytokine gene transfer enhances antitumor immunity.
    Nat Med. 1996 Oct;2(10):1090-5 PMID: 8837606
  2. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Cancer Res. 2001 Dec 1;61(23):8513-9 PMID: 11731436
  3. HLA class I and beta 2-microglobulin expression in frozen and formaldehyde-fixed paraffin sections of neuroblastoma tumors.
    Cancer Res. 1985 Nov;45(11 Pt 2):5976-83 PMID: 3902214
  4. Improving T cell therapy for cancer.
    Annu Rev Immunol. 2007;25:243-65 PMID: 17129181
  5. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
    Blood. 2007 Oct 15;110(8):2793-802 PMID: 17638856
  6. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study.
    J Clin Oncol. 1991 Jan;9(1):152-8 PMID: 1985165
  7. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma.
    Blood. 1998 Sep 15;92(6):1941-9 PMID: 9731051
  8. Reengineered monoclonal antibodies step up to the plate in cancer studies.
    JAMA. 1995 Dec 20;274(23):1821-2 PMID: 7500516
  9. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
    Mol Ther. 2005 Nov;12(5):933-41 PMID: 15979412
  10. Tumour escape: antitumour effectors too much of a good thing?
    Cancer Immunol Immunother. 2004 Mar;53(3):262-74 PMID: 14685780
  11. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.
    Clin Cancer Res. 1998 Nov;4(11):2801-5 PMID: 9829745
  12. Targeting tumours with genetically enhanced T lymphocytes.
    Nat Rev Cancer. 2003 Jan;3(1):35-45 PMID: 12509765
  13. Recent developments in cell-based immune therapy for neuroblastoma.
    J Neuroimmune Pharmacol. 2007 Jun;2(2):134-9 PMID: 18040838
  14. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.
    Anticancer Res. 1999 May-Jun;19(3B):2205-9 PMID: 10472332
  15. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
    J Immunol. 2008 Feb 15;180(4):2089-98 PMID: 18250414
  16. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.
    Cancer Immunol Immunother. 1992;35(3):199-204 PMID: 1638557
  17. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
    Nat Med. 2008 Nov;14(11):1264-70 PMID: 18978797
  18. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor.
    J Pediatr Surg. 2007 Jan;42(1):54-61; discussion 61 PMID: 17208541
  19. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Recent Results Cancer Res. 2002;159:123-33 PMID: 11785836
  20. Is more better? Dose intensity in neuroblastoma.
    J Clin Oncol. 1991 Jun;9(6):902-4 PMID: 2033426
  21. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma.
    J Clin Oncol. 1991 Jun;9(6):1045-9 PMID: 2033418
  22. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin.
    J Immunother. 2007 Feb-Mar;30(2):227-33 PMID: 17471169
  23. Cellular cytotoxicity mediated by isotype-switch variants of a monoclonal antibody to human neuroblastoma.
    Br J Cancer. 1991 Sep;64(3):445-50 PMID: 1911183
  24. Mechanisms of immune evasion of human neuroblastoma.
    Cancer Lett. 2005 Oct 18;228(1-2):155-61 PMID: 15923080
  25. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
    Science. 2008 Aug 15;321(5891):974-7 PMID: 18703743
  26. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.
    J Exp Med. 2004 Dec 20;200(12):1581-92 PMID: 15596524
  27. Lymphotactin: a cytokine that represents a new class of chemokine.
    Science. 1994 Nov 25;266(5189):1395-9 PMID: 7973732
  28. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.
    Br J Cancer. 2003 May 19;88(10):1527-36 PMID: 12771917
  29. Establishment of anti-human neuroblastoma-selective isotype-switch variants.
    J Immunol Methods. 1992 Jan 21;146(1):63-70 PMID: 1735783
  30. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA.
    Gene Ther. 1999 Feb;6(2):300-4 PMID: 10435115
  31. Tumor-specific T-bodies: towards clinical application.
    Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):131-6 PMID: 9435856
  32. Vaccine therapies for pediatric malignancies.
    Cancer J. 2005 Jul-Aug;11(4):331-9 PMID: 16197723
  33. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors.
    Int J Cancer. 1996 Oct 21;69(5):375-80 PMID: 8900370
  34. Immunogenicity of human neuroblastoma.
    Ann N Y Acad Sci. 2004 Dec;1028:69-80 PMID: 15650233
  35. Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy.
    Med Pediatr Oncol. 2000 Dec;35(6):712-5 PMID: 11107153
  36. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma.
    Hum Gene Ther. 1998 Jun 10;9(9):1303-11 PMID: 9650615
  37. Neuroblastoma.
    Lancet. 2007 Jun 23;369(9579):2106-20 PMID: 17586306
  38. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Mol Ther. 2007 Apr;15(4):825-33 PMID: 17299405
  39. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
    N Engl J Med. 1999 Oct 14;341(16):1165-73 PMID: 10519894
  40. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53 PMID: 17255288
  41. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
    Cancer Res. 1984 Dec;44(12 Pt 1):5914-20 PMID: 6498849
  42. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
    Cancer. 2005 Mar 15;103(6):1280-91 PMID: 15693021
  43. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.
    Nat Med. 1996 May;2(5):551-5 PMID: 8616714
  44. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
    Eur J Cancer. 1995;31A(2):261-7 PMID: 7718335
  45. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    J Gene Med. 2004 Jun;6(6):704-11 PMID: 15170741
  46. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
    Lancet. 1995 Jan 7;345(8941):9-13 PMID: 7799740
  47. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
    Blood. 2003 Mar 1;101(5):1718-26 PMID: 12406881
  48. HLA class I antigen abnormalities and immune escape by malignant cells.
    Semin Cancer Biol. 2002 Feb;12(1):3-13 PMID: 11926409
  49. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma.
    Cancer Immunol Immunother. 2005 Apr;54(4):400-6 PMID: 15449039
  50. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
    J Clin Oncol. 1987 Sep;5(9):1430-40 PMID: 3625258
  51. Shed tumor gangliosides and progression of human neuroblastoma.
    Blood. 1990 Apr 1;75(7):1564-7 PMID: 2317562
  52. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    J Clin Oncol. 2003 Apr 15;21(8):1592-601 PMID: 12697885
  53. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes.
    J Immunol. 1985 Jul;135(1):242-6 PMID: 3158702
  54. Antibody-based immunotherapy in high-risk neuroblastoma.
    Expert Rev Mol Med. 2007 Dec 17;9(34):1-21 PMID: 18081947
Article Info
Journal
Current pharmaceutical design
Abbr.
Curr Pharm Des
ISSN
1873-4286
DOI
10.2174/138161209787315765
Email
culouis@txccc.org
Published
2009-00-00
Pages
424-9
Language
English
Region
United Arab Emirates
NLM ID
9602487
PMCID
PMC4122212
Subset
IM
Grants
NCI NIH HHS · K12 CA090433 · United States
NCI NIH HHS · P01 CA094237 · United States
NCI NIH HHS · P01 CA094237-08 · United States
External Links
PubMed source DOI: 10.2174/138161209787315765 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2